Advertisement

Search Results

Advertisement



Your search for Julie A. Schneider, PhD,Julie A. Schneider, PhD matches 2 pages

Showing 1 - 2

issues in oncology

By Julie A. Schneider, PhD; Jennifer J. Gao, MD; Martha B. Donoghue, MD; Lola Fashoyin-Aje, MD, MPH; Jeff Summers, MD; Paul G. Kluetz, MD; Marc R. Theoret, MD; and Richard Pazdur, MD  / February 10, 2023

FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities

OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Julie A. Schneider, PhD, Associate Director for Research Strategy and Partnerships, OCE; Jennifer J. Gao, MD,...

By Julie A. Schneider, PhD; Jennifer J. Gao, MD; Donna R. Rivera, PharmD, MS; Martha B. Donoghue, MD; Gregory H. Reaman, MD, FASCO, Associate Director for Pediatric Oncology, OCE; Rajeshwari Sridhara, PhD; Julia A. Beaver, MD; Paul G. Kluetz, MD; Marc R. Theoret, MD; and Richard Pazdur, MD  / December 25, 2021

The Oncology Center of Excellence Encourages Submissions of Applied Regulatory Science Research Proposals

OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Julie A. Schneider, PhD, Associate Director for Research Strategy and Partnerships, OCE; Jennifer J. Gao, MD,...

Advertisement

Advertisement




Nov
21
Today In Oncology
Firefighters May Be Exposed to Chemicals Associated With Breast Cancer
FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer
Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC
Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo